Haleon PLC Sponsored ADR $HLN Shares Acquired by US Bancorp DE

US Bancorp DE increased its stake in Haleon PLC Sponsored ADR (NYSE:HLN) by 5.5% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 749,052 shares of the company’s stock after buying an additional 39,235 shares during the quarter. US Bancorp DE’s holdings in Haleon were worth $7,768,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the stock. Farther Finance Advisors LLC grew its stake in Haleon by 8.8% during the 1st quarter. Farther Finance Advisors LLC now owns 12,861 shares of the company’s stock valued at $131,000 after purchasing an additional 1,041 shares in the last quarter. Apollon Wealth Management LLC grew its stake in Haleon by 5.4% during the 1st quarter. Apollon Wealth Management LLC now owns 21,722 shares of the company’s stock valued at $224,000 after purchasing an additional 1,111 shares in the last quarter. Holistic Financial Partners grew its stake in Haleon by 9.6% during the 1st quarter. Holistic Financial Partners now owns 13,379 shares of the company’s stock valued at $138,000 after purchasing an additional 1,172 shares in the last quarter. AE Wealth Management LLC grew its stake in Haleon by 6.5% during the 1st quarter. AE Wealth Management LLC now owns 19,323 shares of the company’s stock valued at $199,000 after purchasing an additional 1,186 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its stake in Haleon by 33.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after purchasing an additional 1,203 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Trading Down 0.4%

Shares of NYSE HLN opened at $8.99 on Monday. The company has a market cap of $40.01 billion, a price-to-earnings ratio of 23.04, a price-to-earnings-growth ratio of 2.64 and a beta of 0.20. Haleon PLC Sponsored ADR has a 12-month low of $8.71 and a 12-month high of $11.42. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.48. The stock’s 50 day simple moving average is $9.42 and its 200 day simple moving average is $10.02.

Haleon Increases Dividend

The business also recently declared a semi-annual dividend, which was paid on Thursday, September 18th. Investors of record on Friday, August 15th were issued a $0.0555 dividend. This is a positive change from Haleon’s previous semi-annual dividend of $0.05. The ex-dividend date of this dividend was Friday, August 15th. This represents a dividend yield of 190.0%. Haleon’s dividend payout ratio (DPR) is 28.21%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. The Goldman Sachs Group raised Haleon from a “neutral” rating to a “buy” rating in a report on Wednesday, September 10th. Barclays downgraded Haleon from an “overweight” rating to an “equal weight” rating in a report on Tuesday, September 16th. Wall Street Zen downgraded Haleon from a “buy” rating to a “hold” rating in a report on Saturday, July 12th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, Haleon currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.33.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.